Epitopea
PrivateLast Round
VC Round
Oct 24, 2024
Total Funding Raised
$14.26M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Epitopea operates in Healthcare & Life Sciences and is based in Cambridge. Its latest recorded funding round was a VC Round in October 2024.
Epitopea is a biotechnology company developing off-the-shelf RNA-based cancer immunotherapies that target a novel class of tumor-specific antigens.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Epitopea Comparables
Compare Epitopea with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Enara Bio | 84% | |
| Hervolution Therapeutics | 81% | |
| Cartography Biosciences | 80% |
For institutional investors. Book with your work email.
Epitopea Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Oct 24, 2024 | ||||
| Grant | Sep 12, 2024 | ||||
| Seed | Apr 25, 2022 |
For institutional investors. Book with your work email.
Epitopea Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| Investissement Québec | VC Round |
| CTI Life Sciences Fund | VC Round, Seed |
| IRICoR | VC Round |
| Fonds de solidarité FTQ | VC Round, Seed |
| Consortium Québécois sur la découverte du médicament | Grant |
| Advent Life Sciences | VC Round, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 47% MoM, reaching 3.1K.
- Apr 23, 2026
Susana Banerjee appointed Chief Investigator for OVACT trial.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 10, 2026
Epitopea Ltd is developing its off-the-shelf messenger (m)RNA cancer vaccine, CryptiVax-1001, in a Phase I/Ib OVACT trial for women with advanced high-grade serous ovarian cancer in the United Kingdom, assessing safety, tolerability, and early efficacy signs on Nov 10th '26.
For institutional investors. Book with your work email.
Epitopea Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Epitopea's valuation, stock price, and market status.
Is Epitopea a public or private company?
Epitopea is a private company.
What is the current stock price of Epitopea?
Epitopea is a private company, so its shares have no public market price. Caplight tracks Epitopea's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Epitopea worth (valuation)?
Valuation information for Epitopea is not publicly available.
Can I buy Epitopea stock?
Epitopea shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Epitopea's last funding round?
Epitopea's most recent funding round was VC Round on October 24, 2024.
Who are the main investors in Epitopea?
Key investors in Epitopea include Investissement Québec, CTI Life Sciences Fund, Advent Life Sciences, adMare BioInnovations.
Will Epitopea IPO soon?
No public IPO plans have been announced for Epitopea.
How can I track Epitopea secondary market activity?
Caplight tracks bids, offers, and trades in Epitopea's shares on secondary markets.